NCT06081140

Brief Summary

Tolerance and palatability of short-term supplementation with a whole-food dietary formulation based on hemp oil, calamari oil, and broccoli was evaluated in healthy adults. This was a 10-day open-label, prospective, controlled trial (n=14) in which participants acted as their own controls to receive daily intervention standardized to contain 15 mg phytocannabinoids, 230 mg omega-3 fatty acids, and 5 mg glucoraphanin. The primary objective was to evaluate gastrointestinal tolerability and acceptability. The study demonstrated that daily ingestion of the investigational product was well tolerated with no or minor adverse events, and a good palatability. The secondary objectives were to access parameters of blood biochemistry, liver enzymes, biomarkers of immune and oxi-dative health, as well as phytocannabinoid profiles in urine.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
14

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 26, 2019

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 26, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 26, 2019

Completed
4.3 years until next milestone

First Submitted

Initial submission to the registry

September 25, 2023

Completed
18 days until next milestone

First Posted

Study publicly available on registry

October 13, 2023

Completed
Last Updated

October 13, 2023

Status Verified

October 1, 2023

Enrollment Period

1 month

First QC Date

September 25, 2023

Last Update Submit

October 9, 2023

Conditions

Keywords

whole foodbotanicaldietary supplementbioactive componentsantioxidantshemp oil complexECSNutrition

Outcome Measures

Primary Outcomes (2)

  • Tolerance

    gastrointestinal and general health measured by daily questionnaire, this is a numbered scale from 1-9 from the Global Quality of Life scale

    10 days

  • palatability

    palatability of Standard Process Hemp Oil Complex by questionnaire scale.

    10 days

Secondary Outcomes (3)

  • Oxidative Stress Biomarkers

    1 month

  • Liver Enzymes

    1 month

  • Medical Symptom Questionnaire (MSQ)

    10 days

Study Arms (1)

Supplementation

EXPERIMENTAL

Participants were enrolled at baseline where all outcome measures were collected. Once baseline visit was complete, participants started with the supplementation of Hemp Oil Complex by Standard Process. After 10 days, outcome measures were collected.

Dietary Supplement: Standard Process Hemp Oil Complex

Interventions

10 days of supplementation to determine the tolerance and palatability of Standard Process Hemp Oil Complex.

Supplementation

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject is between 18 and 75 years old
  • Subject is a male or a non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit, and is not actively planning a pregnancy
  • Subject has at least two week wash out period between completion of a previous research study that required ingestion of any study food or drug, and their start in the current study
  • No allergy to any study products
  • Willingness to comply with study protocol for 10 days

You may not qualify if:

  • Subjects who are experiencing any adverse events due to any nutraceutical, OTC, pharmaceutical, or investigational products
  • Subjects may not receive any other investigational products not part of normal clinical care
  • Lipid lowering drugs or the use of anticoagulant medications in the preceding 4 weeks and for duration of trial
  • Subjects with untreated endocrine, neurological, or infectious disease
  • Subjects with a current diagnosis or personal history of: significant liver or kidney disease, autoimmune disorders, deep vein thrombosis, history of cancer
  • Serious medical illness including a history of attempted suicide
  • Use of ethanol within 24 hours of the evaluation visits (baseline, and end of the study visit
  • Do not comply with the study protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Standard Process Nutrition Innovation Center

Kannapolis, North Carolina, 28081, United States

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 25, 2023

First Posted

October 13, 2023

Study Start

April 26, 2019

Primary Completion

May 26, 2019

Study Completion

May 26, 2019

Last Updated

October 13, 2023

Record last verified: 2023-10

Locations